Bruton's tyrosine kinase (Btk) is a member of a recently identified family of tyrosine kinases, including Itk, Tec, Txk, Bmx, and Drosophila Src28C, characterized by an N-terminal pleckstrin homology domain, a proline-rich region, and Src homology 3 (SH3), SH2, and SH1 domains (42) . All lack the negative regulatory C-terminal tyrosine residue and the Nterminal myristoylation site characteristic of Src family kinases. Btk family members are expressed in hematopoietic tissues, livers, kidneys, hearts, lungs, and ovaries (42) . Src family kinases are ubiquitously expressed, with some members displaying exclusive expression in hematopoietic tissues and the brain (9) .
The activation of Btk is associated with an increase in tyrosine phosphorylation of Btk and increased catalytic activity. Btk is activated by cell surface stimulation of the interleukin-5 (IL-5) receptor, IL-6 receptor, the high-affinity immunoglobulin E (IgE) receptor (FcεRI), and the B-cell receptor (sIgM) (2, 12, 19, 28, 44, 45) . Defects in the gene encoding Btk lead to human X-linked agammaglobulinemia (49, 50) and murine X-linked immunodeficiency (40, 48) . These diseases are characterized by a block in B-cell development and defects in B-cell signaling.
Antigen receptor stimulation of B cells induces the enzymatic activation and tyrosine phosphorylation of three distinct families of nonreceptor cytoplasmic tyrosine kinases, the Src family, the Syk family, and the Btk family (reviewed in reference 3). Temporally, Src family kinases are activated first (within seconds) and are followed by Btk and then Syk family kinases (within minutes) (44) . This sequential activation potentially places Btk and Syk downstream of Src family kinases. It has been demonstrated that the SH3 domains of Lyn, Fyn, and Hck directly bind a proline-rich domain in the Btk unique region (1, 7, 51) . However, a physical association of full-length Btk with Src family kinases was not detected in vivo or in vitro.
Recently, overexpression of both Lyn and Btk in a vaccinia virus expression system demonstrated that Lyn can phosphorylate Btk (41) . Lyn transphosphorylates Btk on Y-551 in the catalytic domain (41) , a site homologous to the Src family kinase consensus autophosphorylation site (15, 24) . This results in a 5-to 10-fold increase in Btk enzymatic activity (41) . The increase in activity also leads to increased autophosphorylation at Y-223 in the SH3 domain (38) . The identical phosphopeptides were generated after cross-linking of the B-cell antigen receptor, indicating that these tyrosine phosphorylation sites are physiologically relevant and are likely induced by B-cell Src family kinases (41) .
To genetically define the functional relationship between Btk and Src family kinases, we made use of a gain-of-function mutant of Btk which had been identified by a random mutagenesis scheme (24) . Btk with a point mutation in the pleckstrin homology domain (E-413K [E41K]) was found to transform NIH 3T3 cells in culture and induce factor-independent growth of an IL-5-dependent B cell line (24) . This activated allele, btk*, encodes a protein which tyrosine phosphorylates in vivo (24) . Analysis of Btk* revealed that it is phosphorylated at Y-551 and Y-223 when expressed in NIH 3T3 cells (38) , suggesting that the E41K mutation activates Btk in a manner analogous to that of B-cell stimulation.
In this study we used a functional assay to test the requirement for Src family kinase activity in the activation of Btk*. This genetic test was performed in fibroblasts in which the growth of colonies in soft agar is used as a quantitative measurement of synergy or inhibition between different genes. Using this strategy, we demonstrated that Btk activation is critically dependent upon the dose of Src family kinase activity.
MATERIALS AND METHODS
Plasmid construction and generation of virus stocks. Different btk forms were cloned into the retroviral expression vector pSR␣MSVtkneo (31) by using a unique NotI site 3Ј of the retroviral long terminal repeat (24) . Mutant src E378G (23), generously provided by C. Seidel-Dugan and J. Brugge, was expressed by using the retroviral expression vector pLNCX. Wild-type csk and csk K222R (16) were expressed by using the pLXSH retroviral vector (30) .
Helper-free retroviruses were generated by transient cotransfection of 293T cells (39) (provided by D. Baltimore, Massachusetts Institute of Technology) with retroviral constructs and a ⌿ Ϫ ecotropic packaging plasmid (31) . Supernatant from transfected 293T cells was collected at 36 to 50 h posttransfection. Viral titers were determined indirectly by measuring protein expression at 48 to 72 h after infection of Rat-2 cells by Western blotting (immunoblotting). Viral stocks were normalized to give equivalent levels of protein expression for all samples.
Soft-agar transformation assays. Soft-agar transformation assays were performed as described previously (24, 31) . Rat-2 cell lines expressing Neo, Src E378G, Csk, and Csk K222R were generated by retroviral infection and drug selection (G418 or hygromycin) for 5 to 7 days. Cells were then infected with retroviruses encoding btk forms, grown for 48 to 72 h, and then plated in soft agar at a density of 10 4 cells per 6-cm-diameter dish. The samples were plated in duplicate in medium containing 20% fetal calf serum. Colonies equal to and larger than 0.5 mm in diameter were counted 2 to 3 weeks after plating.
Western blotting. Western blotting was performed as described previously (24) . Cells were lysed in boiling sodium dodecyl sulfate (SDS)-containing sample buffer. Solubilized proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose filters, and probed with specific antibodies. Samples were analyzed with polyclonal antibodies directed to the N-terminal region of Btk (N2) (24, 49) , polyclonal antibodies recognizing Csk (16), anti-Src (␣-Src) monoclonal antibody 327 (25) (generously provided by J. Brugge), and ␣-phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology Inc.).
In vivo 32 P labeling and phosphopeptide mapping. Phosphopeptide mapping of 32 P-labeled Btk was essentially performed as described by Park et al. (38) . Rat-2 cell lines expressing Neo, Csk, Csk K222R, or Src E378G were infected with retroviruses encoding btk*. At 48 to 72 h after infection, 5 ϫ 10 6 cells were incubated with 1 mCi of 32 P i in 2 ml of phosphate-free Dulbecco modified Eagle medium supplemented with dialyzed fetal calf serum (5%). After 3 h, cells were lysed in 20 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid) (pH 7.4)-100 mM NaCl-3% Triton X-100-10% glycerol-2 mM EDTA-1 mM Na 3 VO 4 -10 mM NaF-1 mM phenylmethylsulfonyl fluoride. Btk was immunoprecipitated with 5 g of affinity-purified ␣-Btk antibody (N2). Immunoprecipitates were resolved by SDS-PAGE, blotted onto a nitrocellulose membrane, and visualized by autoradiography. 32 P-labeled Btk protein was excised from the membrane and digested with 15 g of TPCK (N-tosyl-L-phenylalanine chloromethyl ketone)-trypsin (Sigma) twice for 3 h at 37ЊC in 50 mM NH 4 CO 3 . The samples were lyophilized and treated with performic acid for 1 h at 4ЊC. Phosphopeptides were then resolved by thin-layer electrophoresis (pH 1.9) followed by chromatography in phosphochromatography buffer (4) . Phosphopeptide maps were then visualized by autoradiography.
RESULTS

Src E378G activates Btk* and synergizes in transformation.
The criteria for a transformed phenotype of fibroblasts include the growth of colonies in soft agar, indicating a loss of substratum adherence, and acidification of the medium, indicating elevated metabolic rates in cells. Wild-type Btk did not transform NIH 3T3 cells. In contrast, NIH 3T3 cells expressing Btk* formed colonies in soft agar (24) . Btk* is only weakly transforming in rat fibroblasts when compared with NIH 3T3 cells (23a) . We utilized this reduced activity to study the synergy between cooperating genes in Rat-2 cells. Btk* was introduced into Rat-2 fibroblasts by retroviral infection and was analyzed by immunoblot analysis using ␣-Btk antibodies. Immunoblots showed Btk* expression in Rat-2 cells infected with Btk*-encoding retrovirus (Fig. 1 ), but only a small number (Ͻ10) of small colonies (Ͻ0.5 mm in diameter) per 10 4 cells plated were visible after 3 weeks in soft agar (Fig. 2) .
If Btk* transforming activity is dependent on endogenous Src family kinase activity, then an increase in Src activity is predicted to lead to an increase in Btk*-mediated transformation. The tyrosine kinase activity of c-Src is regulated through phosphorylation of two tyrosine sites (reviewed in reference 10). Tyrosine 416 (Y-416) is an autophosphorylation site in the catalytic domain of c-Src, which elevates Src kinase activity when phosphorylated. Downregulation of Src activity results from transphosphorylation of Y-527 in the C terminus by the carboxyl-terminal Src kinase (Csk) (33, 37) .
To test the idea that the activation of Src leads to stimulation of Btk*-mediated transformation, we required a system in which Src is constitutively activated but not transforming in fibroblasts. Several activated mutants of c-Src, including c-Src with a mutation in the regulatory tyrosine residue (Y527F), have been identified. This mutant escapes Csk regulation, exhibits elevated tyrosine kinase activity (reviewed in reference 10), and is highly transforming in rodent fibroblasts. In contrast, an activating mutation in the c-Src kinase domain (E378G) (23) transforms chicken cells efficiently (22, 46) but forms only a few small colonies in soft agar when expressed in Rat-2 cells (16a). For this reason, Rat-2 cells expressing Src E378G were utilized in transformation assays with Btk*. Cell lines were generated by using retroviruses encoding both Src E378G and the neo gene, allowing the enrichment of cells expressing Src E378G by selection in G418. Immunoblot analysis of Src expression showed that Src E378G was expressed about twofold over endogenous c-Src (Fig. 1) . Similar to the results with cells expressing Btk*, cells expressing Src E378G alone formed a small number (Ͻ10) of small colonies in soft agar and no medium acidification was observed (Fig. 2) . In contrast, coexpression of Btk* and Src E378G resulted in a dramatic increase in the number (Ͼ300 after 3 weeks) and size (0.5 to 1.5 mm in diameter) of colonies (Fig. 2 ). Colonies were visible after 10 to 14 days, and the media were acidified after 3 weeks in culture. This increase in transformation activity is comparable to the synergy observed with coexpression of ras and myc (21) or of the bcr-abl tyrosine kinase oncogene and myc (26) .
Expression of either Btk* alone or Src E378G alone did not significantly increase intracellular phosphotyrosine levels (Fig.  1) . As previously described, tyrosine phosphorylation was detected on Btk* when expressed alone (24) . Coexpression with Src E378G increased the level of tyrosine phosphorylation on Btk* by three-to fivefold ( Fig. 1 and 3 ). This was accompanied by a twofold increase in Btk* kinase activity (data not shown). No change in the tyrosine phosphorylation or kinase activity of Src was detected. Analysis of whole-cell lysates revealed the appearance of a highly tyrosine-phosphorylated 70-kDa cellular protein (pp70) in cells coexpressing Btk* and Src E378G (Fig. 1) . Phosphorylation of pp70 was detected only in cells coexpressing Btk* and Src E378G in four independent experiments.
Functional interaction of Btk* with Csk. To determine the effect of inactivation of Src family kinases on Btk*-mediated transformation, we utilized overexpression of Csk or kinaseinactive Csk (K222R). Previous studies had demonstrated that overexpression of Csk can reduce the activity of c-Src (43) . If Btk* activation requires endogenous Src family kinase activity, then wild-type Csk may suppress Btk* activation. Conversely, Csk K222R should either have no effect on Btk* activation or, alternatively, act as a dominant negative molecule, causing Btk* activation by derepression of endogenous Src family kinases.
Rat-2 cell lines which overexpress either wild-type Csk or Csk K222R were generated. Expression vectors encoding Csk molecules were linked to the hygromycin resistance gene, and cells were enriched for Csk expression by drug selection. Immunoblotting demonstrated that recombinant Csk forms were overexpressed 5-to 10-fold over endogenous Csk levels in Rat-2 cells (Fig. 4) . These cell lines were subsequently infected with retroviruses expressing Btk* to determine the effect on Btk* transforming activity. Coexpression of Btk* with Csk resulted in a three-to fivefold decrease in Btk* tyrosine phosphorylation ( Fig. 3 and 4) . In contrast, coexpression of Btk* with Csk K222R resulted in a 1.5-fold increase in Btk* tyrosine phosphorylation and a 5-fold increase in total Btk* phosphorylation (Fig. 3) . In addition, tyrosine phosphorylation of pp70 was significantly increased (Fig. 4) . When plated in soft agar, cells coexpressing Btk* with Csk K222R formed a large number (Ͼ150) of medium-sized (Ͼ0.5 mm in diameter) colonies, mimicking the transformed phenotype displayed by Btk* and Src E378G coexpression (Table 1) . Taken together, these results suggest that Csk K222R functions as a dominant negative molecule and regulates Btk* indirectly through derepression of endogenous Src kinases.
The reduced tyrosine phosphorylation of Btk*, when coexpressed with Csk, strongly supports the conclusion that endogenous Src kinases are responsible for activating Btk*. Previous work has shown that Src E378G is phosphorylated on Y-527 (46) , suggesting that it may still be under partial control by Csk. VOL. 16, 1996 REGULATION OF Btk BY Src FAMILY TYROSINE KINASES 3467
To determine if an increased dose of Csk could influence Btk* complementation with Src E378G, all three genes (csk, btk*, and src E378G) were coexpressed in Rat-2 cells. Rat-2 cell lines coexpressing Csk and Src E378G were generated by using double selection in hygromycin and G418. These cells were then superinfected with retrovirus encoding Btk* and analyzed for growth in soft agar, for protein expression, and for total phosphotyrosine. Cells expressing Csk with Btk* and Src E378G displayed a 35% decrease in soft-agar colony number when compared with that of cells expressing only Btk* with Src E378G (Table 1) . Csk K222R had no additional effect on agar colony growth induced by Btk* and Src E378G coexpression. Anti-phosphotyrosine antibody analysis of whole-cell lysates showed that expression of either Csk or Csk K222R had no detectable effect on the increase in cellular phosphotyrosine levels when Btk* and Src E378G were coexpressed (data not shown). These results suggest that while Csk can readily downregulate endogenous wild-type Src family kinases, it is less effective in suppressing Src E378G. Activation of Btk* is accompanied by an increase in tyrosine phosphorylation at Y-223 and Y-551. Enzymatic activation of Btk by Src family kinases in vitro is the result of initial transphosphorylation at Y-551, followed by Btk autophosphorylation at Y-223 (38, 41) . To determine if this two-step activation mechanism for Btk is reproduced by Src and Btk complementation, the phosphorylation sites of Btk* in Rat-2 cells were analyzed by tryptic phosphopeptide mapping. Rat-2 cells were incubated in phosphate-free medium containing 32 P i . Phosphorylated Btk* was immunoprecipitated from cell extracts and digested with trypsin as described in Materials and Methods.
Previous tryptic phosphopeptide analyses of phosphorylated Btk revealed the presence of two major tyrosine-phosphorylated peptides, PY1 and PY2, and several serine-phosphorylated peptides (38, 41) . Mutational analysis demonstrated that PY1 harbors phosphorylated Y-551 (41), while direct sequencing of PY2 demonstrated the presence of phosphorylated Y-223 (38) . Btk* in Rat-2 cells displayed a basal level of phosphorylation on Y-551 and Y-223 (Fig. 5A) . Coexpression with Csk reduced Y-551 phosphorylation to undetectable levels and Y-223 phosphorylation to barely detectable levels (Fig. 5B) . The expression of Btk* with Src E378G significantly increased the phosphorylation of both Y-551 and Y-223, as well as phosphorylation of several phosphoserine-containing peptides (Fig.  5D ). In contrast, phosphopeptide mapping of Src from cells coexpressing Btk* and Src E378G revealed no detectable change in Src phosphorylation (data not shown). A 50% increase in Y-551 phosphorylation was detected when Btk* was coexpressed with Csk K222R (Fig. 5C ). Although Csk K222R did not induce a significant increase in Y-223 phosphorylation, an increase in the number of Btk*-derived serine-phosphorylated peptides was observed. These data demonstrate that activated Src kinases synergize with Btk*, coincident with increased phosphorylation of Y-551 and Y-223.
Structural and functional requirements for Btk activation. The activation of Btk catalytic activity leads to autophosphorylation of Y-223 in the SH3 domain. The SH3 domain functions as a negative regulatory element in Src family kinases (32, 36, 47) and Abl tyrosine kinases (13, 18) . Phosphorylation of Y-223 within the binding groove of the SH3 domain may increase Btk* activity by relieving negative regulatory SH3-mediated protein-protein interactions (38) . This model predicts that activation of Btk by Src E378G requires (i) the E41K (Btk*) mutation, (ii) kinase activity, (iii) availability of Y-551 for phosphorylation, and (iv) possible potentiation by deletion of the SH3 domain.
To test this model, Btk* double mutants were coexpressed with Src E378G in Rat-2 cells. The mutants generated included Btk*K430R (kinase inactive), Btk*Y551F (transphosphorylation site mutant), and Btk*⌬SH3 (SH3 domain deletion mutant) (24) , which were compared with wild-type Btk and Btk* for transforming activity. The results (Fig. 6) show that cells expressing wild-type Btk with Src E378G exhibited no growth in soft agar. Both the putative ATP binding site mutation in the kinase domain (K430R) and the transphosphorylation site mutation (Y551F) abolish the ability of Btk* to be activated by Src E378G. Tyrosine phosphorylation of pp70 was not detectable in cells expressing Btk*K430R, Btk*Y551F, or wild-type Btk. a Rat-2 cells which express the hygromycin resistance gene (hygro), Csk, and Csk K222R alone or in combination with Src E378G were infected with retroviruses encoding neo or btk*. At 48 to 72 h postinfection, these cell lines were plated into soft agar medium containing 20% fetal calf serum at a density of 10 4 cells per plate. Soft-agar colony growth was determined at 3 weeks after plating. Colonies equal to and larger than 0.5 mm in diameter were counted. Colony numbers are the averages of two independent experiments rounded off to two significant figures.
Wild-type Btk itself was tyrosine phosphorylated above background levels in the presence of Src E378G (Fig. 7) . This suggests that some activation of Btk did occur, although it was not sufficient for inducing growth in soft agar.
A deletion of the SH3 domain potentiated activation of Btk* by Src E378G. Btk*⌬SH3 by itself was not transforming in Rat-2 cells. However, colonies formed by cells coexpressing Btk*⌬SH3 and Src E378G were larger (Ͼ1 to 2 mm in diameter) and more numerous (two-to threefold more) than colonies formed by coexpression of Btk* and Src E378G. Cells expressing Btk*⌬SH3 and Src E378G formed colonies and acidified the media more rapidly (within 1 to 2 weeks) than did cells expressing Btk* and Src E378G. Anti-phosphotyrosine antibody analysis of whole-cell lysates showed that tyrosine phosphorylation of pp70 was increased two-to threefold in cells expressing Btk*⌬SH3 compared with that in cells expressing Btk* (Fig. 7) . Tyrosine phosphorylation of Btk*⌬SH3 itself was lower compared with that of Btk*. This may be due to the loss of Y-223 in the deleted region. Deletion of the SH3 domain may change the conformation of Btk*, making it more accessible to Y-551 phosphorylation and/or activation by Src E378G. Another possibility is that the SH3 domain exerts a negative influence on Btk*-mediated biological activity which is relieved by deletion or phosphorylation of this domain.
DISCUSSION
Direct activation of Btk by Src family kinases. Src family kinases exert their pleiotropic effects by phosphorylating other proteins, including other classes of tyrosine kinases. In fibroblasts and brain tissue, Src family kinases phosphorylate and activate the focal adhesion kinase pp125Fak (6, 14) . In a lyndeficient chicken B-cell line, cross-linking of sIgM fails to activate Syk, indicating that Lyn functions upstream of Syk (20) . Our data, in combination with other studies (27, 41, 44) , suggest that Src family kinases also function upstream of Btk.
Coexpression of Src E378G with Btk* resulted in an increase in Y-551 phosphorylation, which correlated with complementation for transformation activity. Both tyrosine phosphorylation of Btk and biological synergy were blocked by a mutation in Y-551. Studies using vaccinia virus to overexpress both Btk and Lyn demonstrated that Lyn phosphorylates Btk on Y-551 (41) . Contrary to this, a recent report claimed that Y-551 is a Btk autophosphorylation site and that Src family kinases activate Btk through a non-phosphorylation-mediated mechanism (27) . Mahajan et al. (27) Indirect suppression of Btk by Csk. Csk is normally present at sufficient levels in fibroblasts to fully inhibit endogenous Src family kinases. Halving the gene dose of Csk does not appear to increase Src activity, but Src is activated in fibroblasts lacking Csk (17, 34) . However, Csk levels are inadequate to fully suppress Src family kinase activity under some conditions. For example, overexpression of Src with the SH2 and SH3 domaincontaining adapter protein Crk (29) results in transformation, unless Csk is also overexpressed (43) . In T cells, overexpression of Csk leads to downregulation of T-cell-receptor-induced tyrosine phosphorylation and lymphokine production (8) . Since these effects are dependent on the activation of the Src family kinases Fyn and Lck, it appears that endogenous Csk levels permit activation of those kinases by the T-cell receptor, while overexpression of Csk can prevent activation.
When Btk* was expressed in cells that overexpress Csk, the phosphorylation of Btk* on Y-551 and Y-223 was dramatically reduced. No new tyrosine phosphorylation sites were detected by phosphopeptide mapping. Btk lacks a regulatory tyrosine residue homologous to Src's Y-527 in the C terminus (42, 49, 50) . These data argue that Btk is unlikely to be a direct substrate of Csk. VOL. 16, 1996 REGULATION OF Btk BY Src FAMILY TYROSINE KINASES 3469
Overexpression of kinase-inactive Csk resulted in the activation of Btk* activity. Like wild-type Csk, Csk K222R localizes to cellular sites of c-Src activity (16) . The overexpressed Csk mutant may compete with and displace endogenous wildtype Csk for binding sites, thus preventing the inactivation of Src kinases. Csk K222R likely functions as a dominant negative molecule, derepressing endogenous Src kinases, which in turn stimulate Btk*.
These results suggest that in cells expressing Btk*, Csk becomes limiting for maintaining endogenous Src family kinases in an inactive state. Overexpression of active or inactive Csk can thus modulate the activity of endogenous Src in cells overexpressing Btk*. The binding of the proline-rich region of Btk* to the SH3 domains of endogenous Src kinases could partially activate Src by competing for interactions that normally maintain Src in an inactive state. However, increased Src kinase activity was not detected in cells coexpressing Btk* and Src E378G or kinase-defective Csk. Btk* kinase activity is clearly required, since Btk*K430R was not transforming and did not increase tyrosine phosphorylation of cell proteins.
Regulation of Btk activation via its SH3 domain. The major Btk autophosphorylation site, Y-223, is located in the SH3 domain (38) . Deletion of the SH3 domain did not appear to significantly activate wild-type Btk. However, some increase in Btk*-mediated transformation did occur (24) . This differs from c-Abl, in which an SH3 domain deletion is sufficient for oncogenic activation (13, 18) . Here we have shown that the synergy between Src E378G and Btk* is significantly increased when the SH3 domain of Btk* is deleted. Very recent work has shown that the mutation of Y-223 to phenylalanine activates Btk* transforming activity in a manner similar to that of deletion of the SH3 domain (38) . SH3 domains are known to interact with proline-rich sequences. Phosphorylation of Y-138 in the c-Src SH3 domain by the platelet-derived growth factor receptor reduces the binding affinity for proline-rich peptides (5) . Structural comparisons with the Fyn SH3 domain place Btk Y-223 in a highly conserved region of the peptide binding groove (35) . Thus, phosphorylation at Y-223 may either prevent or increase the association with factors that regulate Btk activity.
In vitro binding experiments have shown that the Btk SH3 domain can interact with the ubiquitous tyrosine kinase substrate c-Cbl (11) . The Caenorhabditis elegans homolog of cbl, sli-1, functions as a suppressor of tyrosine kinase signals necessary for vulval development (52) . Although the function of mammalian Cbl is unknown, it may exert a regulatory effect on Btk and similar tyrosine kinases. Similarly, molecules that influence Btk Y-223 phosphorylation, such as phosphotyrosinespecific phosphatases, may regulate interactions with such factors. Identification of these proteins would allow us to test them for function by using the transformation phenotype observed with Src and Btk coexpression.
Our results lead us to speculate that the interactions between Src family kinases and Btk family kinases represent an important cellular signaling pathway. Both kinase families exhibit wide tissue expression patterns. It is conceivable that in every instance of coexpression, a Btk family member is regulated by an upstream Src family kinase.
